HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiov...
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
About this item
Full title
Author / Creator
Publisher
Washington, DC: American Association for Clinical Chemistry
Journal title
Language
English
Formats
Publication information
Publisher
Washington, DC: American Association for Clinical Chemistry
Subjects
More information
Scope and Contents
Contents
A growing body of evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. For more than 3 decades, HDL cholesterol has been employed as the principal clinical measure of HDL and cardiovascular risk associated with low HDL-ch...
Alternative Titles
Full title
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_854567450
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_854567450
Other Identifiers
ISSN
0009-9147
E-ISSN
1530-8561
DOI
10.1373/clinchem.2010.155333
